Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 6/20 | 0.51 |
| ▸ | WDR5 | P61964 | 2/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.41 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.38 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.38 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1763322 | 0.90 | ELANE (0.54) | ELANEWDR5PDK4 | |
| SCHEMBL34465791 | 0.84 | NR1H2 (0.47) | ELANEWDR5GPR119PDK4 | |
| SCHEMBL1764097 | 0.83 | WDR5 (0.42) | ELANEWDR5PDK4 | |
| SCHEMBL31420555 | 0.79 | GPR119 (0.51) | ELANEGPR119PDK4TBK1 | |
| SCHEMBL16879141 | 0.79 | AR (0.46) | ELANEGPR119CYP2C9TBK1 | |
| SCHEMBL5320102 | 0.77 | PDK4 (0.53) | ELANEGPR119PDK4 | |
| SCHEMBL30745989 | 0.76 | SOS1 (0.42) | ELANEWDR5PDK4 | |
| SCHEMBL27007919 | 0.76 | SOS1 (0.42) | ELANEWDR5PDK4 | |
| SCHEMBL25369348 | 0.76 | GPR119 (0.55) | GPR119 | |
| SCHEMBL20142327 | 0.75 | PDK4 (0.52) | ELANEGPR119PDK4TBK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110118262-A1 | Pyrrolidinyl and Piperidinyl Compounds Useful as NHE-1 Inhibitiors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118262-A1 | Pyrrolidinyl and Piperidinyl Compounds Useful as NHE-1 Inhibitiors | NHERF1, SLC9A1, SLC9A5 | ELANE 1014/4885WDR5 4243/4885GPR119 703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.